TMZ-BioShuttle--a reformulated temozolomide.
There is a large number of effective cytotoxic drugs whose side effect profile, efficacy, and long-term use in man are well understood and documented over decades of use in clinical routine e.g. in the treatment of recurrent glioblastoma multiforme (GBM) and the hormone-refractory prostate cancer (HRPC). Both cancers are insensitive against most chemotherapeutic interventions; they have low response rates and poor prognoses. Some cytotoxic agents can be significantly improved by using modern technology of drug delivery or formulation. We succeeded to enhance the pharmacologic potency with simultaneous reduction of unwanted adverse reactions of the highly efficient chemotherapeutic temozolomide (TMZ) as an example. The TMZ connection to transporter molecules (TMZ-BioShuttle) resulted in a much higher pharmacological effect in glioma cell lines while using reduced doses. This permits the conclusion that a suitable chemistry could realize the ligation of pharmacologically active, but sensitive and highly unstable pharmaceutical ingredients without functional deprivation. The re-formulation of TMZ to TMZ-BioShuttle achieved a nearly 10-fold potential of the established pharmaceutic TMZ far beyond the treatment of brain tumors cells and results in an attractive reformulated drug with enhanced therapeutic index.
Waldeck
Waldemar
W
German Cancer Research Center, Division of Biophysics of Macromolecules, INF 580, D-69120 Heidelberg, Germany.
Wiessler
Manfred
M
Ehemann
Volker
V
Pipkorn
Ruediger
R
Spring
Herbert
H
Debus
Juergen
J
Didinger
Bernd
B
Mueller
Gabriele
G
Langowski
Joerg
J
Braun
Klaus
K
D018906:Antineoplastic Agents, Alkylating / Q000737:chemistry / Q000494:pharmacology; D002352:Carrier Proteins / Q000737:chemistry; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002626:Chemistry, Pharmaceutical / Q000379:methods; D020552:Comet Assay; D053938:DNA Fragmentation / Q000187:drug effects; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000138:chemical synthesis / Q000737:chemistry*; D005909:Glioblastoma / Q000473:pathology; D006801:Humans; D008297:Male; D019913:Nuclear Localization Signals / Q000737:chemistry; D010446:Peptide Fragments / Q000737:chemistry; D011471:Prostatic Neoplasms / Q000473:pathology; D000077204:Temozolomide; D014407:Tumor Cells, Cultured
D018906:Antineoplastic Agents, Alkylating; D002352:Carrier Proteins; D004337:Drug Carriers; D019913:Nuclear Localization Signals; D010446:Peptide Fragments; D003606:Dacarbazine; D000077204:Temozolomide
Cancer Res. 2002 Dec 1;62(23):7018-24
12460922
Neurochem Int. 2001 Jul;39(1):11-8
11311444
Mol Cell Biochem. 1980 Jan 16;29(1):47-57
6154231
Int J Cancer. 1978 Mar 15;21(3):274-81
631930
Angew Chem Int Ed Engl. 2002 Jul 15;41(14):2596-9
12203546
Curr Med Chem. 2005;12(16):1841-58
16101505
Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S81-91
11033430
Biochem Biophys Res Commun. 2007 Dec 21;364(3):656-61
17964537
Proc Natl Acad Sci U S A. 2004 May 4;101(18):6993-8
15118108
Oncol Rep. 2006 Dec;16(6):1253-60
17089046
Expert Rev Anticancer Ther. 2006 Aug;6(8):1187-204
16925485
J Immunol Methods. 1991 Jun 3;139(2):271-9
1710634
Int J Med Sci. 2007 Oct 30;4(5):267-77
18026568
Angew Chem Int Ed Engl. 2001 Jun 1;40(11):2004-2021
11433435
Semin Oncol. 2006 Jun;33(3 Suppl 9):S3-8
16797375
Cancer Chemother Pharmacol. 2003 Dec;52(6):459-64
13680160
Br J Cancer. 1992 Feb;65(2):287-91
1739631
Toxicol Appl Pharmacol. 1996 Nov;141(1):319-29
8917705
Haemophilia. 2007 May;13(3):233-43
17498071
Angew Chem Int Ed Engl. 2006 Jan 30;45(6):896-901
16370010
Cancer Chemother Pharmacol. 2000;45(6):509-12
10854140
Biochem Biophys Res Commun. 2006 Jul 14;345(4):1547-57
16735025
Biochim Biophys Acta. 2008 Jan;1779(1):3-16
18078840
Expert Rev Anticancer Ther. 2001 Jun;1(1):13-9
12113120
Cancer Res. 2003 Aug 15;63(16):4766-72
12941791
Pharmacol Res. 2007 Oct;56(4):275-87
17897837
Drug Discov Today. 2003 Dec 15;8(24):1128-37
14678739
Gan To Kagaku Ryoho. 2008 Mar;35(3):543-7
18347414
Biochemistry. 1994 Aug 9;33(31):9045-51
8049205
Mol Cell Biol. 2003 Nov;23(22):8306-15
14585987
Angew Chem Int Ed Engl. 2004 Jun 14;43(24):3106-16
15199557
Cancer Res. 2000 Oct 1;60(19):5464-9
11034089
J Aerosol Med. 2002 Fall;15(3):245-50
12396412
AAPS PharmSciTech. 2006 Jan 13;7(1):E5
16584164
Expert Opin Emerg Drugs. 2004 May;9(1):135-54
15155140
J Cell Biochem. 2004 Feb 15;91(3):540-52
14755684
Hepatology. 2007 Sep;46(3):759-68
17663418
J Clin Oncol. 2008 Sep 1;26(25):4189-99
18757334
Cancer Lett. 2003 May 8;194(1):125-31
12706866
J Mol Biol. 2002 Apr 26;318(2):237-43
12051833
Anticancer Res. 2006 Mar-Apr;26(2B):1327-36
16619541
Pathol Oncol Res. 2007;13(2):84-90
17607368
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
J Neurosurg. 2003 Mar;98(3):591-8
12650433
Mol Carcinog. 2002 Mar;33(3):163-71
11870882